Pathalys Raises $105m To Pave Path Toward US Commercialization
Series B Follows $150m Series A In January 2023
The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.
